Indications and uses
For the treatment of pain associated with migraine headache.
For the treatment of pain associated with migraine headache.
• For best results, use at the first sign of migraine headache • Adults and children 6 years of age and older (with adult supervision): o Remove cap & safety clip (also see illustration on side carton & insert). o Hold with thumb at bottom of bottle and nozzle between your fingers. o Before using the first time, prime pump by depressing several times. o Place tip o nozzle just past nasal opening (approximately 1/8...
Chamomilla 3C
Natrum Sulphuricum 3C
Sanguinaria Canadensis 3C
Glutathione 1C
Migraine Relief
For the treatment of pain associated with migraine headache.
For nasal use only
if symptoms persist.
ask a health professional before use.
If swallowed, get medical help or contact a Poison Control Center right away.
benzalkonium chloride, glycerin, hydroxyethylcellulose, methylparaben, potassium phosphate monobasic, purified water, sodium chloride, sodium phosphate dibasic
Take at the first sign of migraine headache
Store at room temperature 15°C-29C-29°C (59°F-84°F)
www.migranade.com
Manufactured for Migranade, Inc.
1450 2nd St.
Santa Monica, California 90401-2302
United States
tel: 3104398674
Product of USA Homeopathic
Migranade Migraine Relief
Non-Drowsy
Relief of Migraine Headache
Homeopathic
DIRECTIONS: Adults and children 6 years of age and older (with adult supervision):
1. Remove cap and safety clip. | |
2. Hold with thumb at bottom of bottle and nozzle between your fingers. | |
3. Before using the first time, prime pump by depressing several times. | |
4. Place tip of nozzle just past nasal opening (approximately 1/8”). | |
5. Pump one to two times into each nostril. | |
6. Use as needed every four hours not to exceed three times per 24 hours. if headache persists for more than 48 hours, consult a physician. |
Children under 6 years of age: Consult a doctor before use.
Active Ingredients:
Chamomilla 3C,
Natrum Sulphuricum 3C,
Sanguinaria Canadensis 3C,
Glutathione 1C
Inactive Ingredients:
benzalkonium chloride, glycerin, hydroxyethylcellulose, methlyparaben, potassium phosphate monobasic, purified water, sodium chloride, sodium phosphate dibasic
Warnings:
For nasal use only
Ask a doctor before use if you have
When using this product
Stop use and ask a doctor if symptoms persist.
If pregnant or breast feeding, ask a health professional before use.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Take at the first sign of migraine headache.
Migranade Migraine Relief
Product is naturally dark in color.
Manufactured for:
Migranade Inc.
Santa Monica, California
90401-2302
United States
tel:3104398674
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 95250459-30e4-45c1-b08a-993044f49109 | Product name | 2 | 20250805 |
| 4b7700e3-6e0e-45e5-9d22-6f754d61386e | Product name | 2 | 20250304 |
| 726062af-1135-4707-a1d7-57256991bbf9 | Product name | 2 | 20250226 |
| 362d7abb-94e6-4c60-9a58-266894157713 | Product name | 1 | 20231023 |
| 9badc7be-250a-44ab-aa36-926af3f02679 | Product name | 1 | 20210527 |
| 816b97af-edc5-4060-aff1-b814bdbcad50 | Product name | 1 | 20190415 |
| 26acd337-b838-40ac-bcbc-05c3b81c8712 | Product name | 1 | 20170323 |
| 19c71a3d-ed9c-166b-a7e5-38c250c35631 | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60916-001-01 | 2019-11-27 | C162847 | 48780-1 | 9855e2a2-3a56-60a7-e053-dbdaa90a05bd | Migranade Migraine Relief Nasal Spray |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60916-001-01 | Migranade | 15 mL in 1 BOTTLE, SPRAY | SPRAY | 15 | 1 | |
| 60916-001-01 | Migranade | 1 in 1 CARTON | SPRAY | 1 | 1 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CHAMOMILE | ACTIVE INGREDIENT | FGL3685T2X | 1 | |
| GLUTATHIONE | ACTIVE INGREDIENT | GAN16C9B8O | 1 | |
| SANGUINARIA CANADENSIS ROOT | ACTIVE INGREDIENT | N9288CD508 | 1 | |
| SODIUM SULFATE | ACTIVE INGREDIENT | 0YPR65R21J | 1 | |
| CHAMOMILE | ACTIVE MOIETY | FGL3685T2X | 1 | |
| GLUTATHIONE | ACTIVE MOIETY | GAN16C9B8O | 1 | |
| SANGUINARIA CANADENSIS ROOT | ACTIVE MOIETY | N9288CD508 | 1 | |
| SODIUM SULFATE ANHYDROUS | ACTIVE MOIETY | 36KCS0R750 | 1 | |
| BENZALKONIUM CHLORIDE | INACTIVE INGREDIENT | F5UM2KM3W7 | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| HYDROXYETHYL CELLULOSE (100 MPA.S AT 2%) | INACTIVE INGREDIENT | R33S7TK2EP | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| POTASSIUM PHOSPHATE, MONOBASIC | INACTIVE INGREDIENT | 4J9FJ0HL51 | 1 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | INACTIVE INGREDIENT | 22ADO53M6F | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60916-001 | 60916-001-01 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SHAMPOO / TOPICAL | 0.2 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / OPHTHALMIC | 0.01 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / PERIDURAL | 8.07 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR | 0.86 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | DROPS / OPHTHALMIC | 0.08 %w/w | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | INJECTION / INTRALESIONAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / DENTAL | 0.4 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRA-ARTERIAL | 278 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | SUSPENSION / ORAL | 66 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION / INTRA-ARTICULAR | 28 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / IONTOPHORESIS | 168.1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, EXTENDED RELEASE / ORAL | 0.17 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRAVITREAL | 6 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | SOLUTION / NASAL | 680 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | 1.35 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / INTRAMUSCULAR | 45 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 226 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / TOPICAL | 0.02 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.8 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION/ DROPS / OPHTHALMIC | 0.02 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / RESPIRATORY (INHALATION) | 43 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | CAPSULE, DELAYED RELEASE / ORAL | 43 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRA-ARTICULAR | 0.24 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRALESIONAL | 0.9 %w/v | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION / INTRAMUSCULAR | 1751 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / AURICULAR (OTIC) | 0.01 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | INJECTION / INTRA-ARTICULAR | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, COATED / ORAL | 0.8 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | PASTE, DENTIFRICE / DENTAL | 0.05 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | LOTION / TOPICAL | 351 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / SUBCUTANEOUS | 90 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, CHEWABLE / ORAL | 20 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | SOLUTION / INTRAVENOUS | 381 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / PARENTERAL | 210 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | CAPSULE, COATED PELLETS / ORAL | 272 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 139.2 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRATUMOR | 1.2 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRASYNOVIAL | 0.9 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / RECTAL | 1808 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / NASAL | 10 mg/1ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVENOUS | 28773 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, CHEWABLE / ORAL | 12 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / OPHTHALMIC | 3 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / EPIDURAL | 30 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / AURICULAR (OTIC) | 0.01 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAPLEURAL | 226 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBMUCOSAL | 16 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / ENDOTRACHEAL | 68 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / SUBCUTANEOUS | 15 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | POWDER, FOR SOLUTION / ORAL | 126 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / TOPICAL | 420 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 4d28d68d-0793-4f45-9dbf-ce38cede000c | 4d28d68d-0793-4f45-9dbf-ce38cede000c | 2014-01-22 | Warnings | 4d28d68d-0793-4f45-9dbf-ce38cede000c 4d28d68d-0793-4f45-9dbf-ce38cede000c |
Adverse event summaries are temporarily unavailable. Other product information remains available.